Search Within

Department of Medicine

Formats
  1. Journal Article (19593)
  2. Meeting Abstract (16038)
  3. Review (1150)
  4. Book Section (934)
  5. Editorial (610)
  6. Research Letter (314)
  7. Conference Paper (301)
  8. Guidelines (295)
  9. Correspondence (236)
  10. Miscellaneous (90)
  11. Book Whole (61)
Groups
  1. Solid Tumor Oncology Division (22321)
  2. Hematologic Malignancies, Division of (13278)
  3. Center for Hematologic Malignancies (11061)
  4. GSK Faculty (10646)
  5. Survivorship Research (9330)
  6. Division of Subspecialty Medicine (7535)

More Groups

People
  1. Robert Motzer (1248)
  2. Howard Scher (1132)
  3. Sergio Giralt (1069)
  4. Miguel-Angel Perales (943)
  5. Clifford Hudis (905)
  6. Jedd Wolchok (905)

More People

Years
  1. 2025 (1071)
  2. 2024 (2291)
  3. 2023 (2452)
  4. 2022 (2621)
  5. 2021 (2534)
  6. 2020 (2563)

More Years

Publications
  1. Journal of Clinical Oncology (6125)
  2. Blood (3722)
  3. Annals of Oncology (1398)
  4. Cancer Research (1238)
  5. Clinical Cancer Research (902)
  6. Biology of Blood and Marrow Transplantation (679)

More Publications

Publishers
  1. American Society of Clinical Oncology (6458)
  2. Elsevier Inc. (4216)
  3. American Society of Hematology (4003)
  4. American Association for Cancer Research (2896)
  5. Oxford University Press (2286)
  6. Nature Publishing Group (2111)

More Publishers

Results (39622)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate
    Meeting Abstract

    Möhler, M.; Janjigian, Y. Y.; Shitara, K.; Garrido, M.; Gallardo, C.; Shen, L.; Yamaguchi, K.; Wyrwicz, L.; Skoczylas, T.; Bragagnoli, A.; more...
    Oncology Research and Treatment (2024)

    Fulltext@MSK | Save
  • Impact of viral aetiology in the Phase 3 HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
    Meeting Abstract

    Chan, S. L.; Kudo, M.; Sangro, B.; Kelley, K.; Furuse, J.; Park, J. W.; Sunpaweravong, P.; Fasolo, A.; Yau, T.; Kawaoka, T.; more...
    Oncology Research and Treatment (2024)

    Fulltext@MSK | Save
  • Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the phase 3 HIMALAYA study
    Meeting Abstract

    Vogel, A.; Chan, S. L.; Furuse, J.; Tak, W. Y.; Masi, G.; Varela, M.; Kim, J. H.; Tanasanvimon, S.; Reig, M.; Dayyani, F.; more...
    Oncology Research and Treatment (2024)

    Fulltext@MSK | Save
  • Four-year overall survival update from the phase 3 HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
    Meeting Abstract

    Sangro, B.; Chan, S. L.; Kelley, K.; Lau, G.; Kudo, M.; Sukeepaisarnjaroen, W.; De Toni, E.; Furuse, J.; Kang, Y. K.; Galle, P. R.; more...
    Oncology Research and Treatment (2024)

    Fulltext@MSK | Save
  • Patient-reported outcomes in patients with metastatic castration-resistant prostate cancer and BRCA1/2 mutations receiving first-line niraparib with abiraterone acetate plus prednisone (Magnitude study)
    Meeting Abstract

    Nguyen, C.; Rathkopf, D. E.; Chi, K. N.; Small, E.; Smith, M.
    Oncology Nursing Forum (2024)

    Fulltext@MSK | Save
  • Final analysis of patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations receiving first-line niraparib with abiraterone acetate plus prednisone (MAGNITUDE Study) for cancer caregivers: A pilot to address existential distress in caregivers of hematopoietic stem cell transplant patients
    Meeting Abstract

    Olivier, K.; Smith, M.; Rathkopf, D. E.; Small, E.; Guckert, M.; Chi, K. N.
    Oncology Nursing Forum (2024)

    Fulltext@MSK | Save
  • Phase II, single-arm, open-label study of dostarlimab monotherapy in previously untreated patients with stage II/III dMMR/MSI-H locally advanced rectal cancer: Trial in progress
    Meeting Abstract

    Cercek, A.; Bachet, J. B.; Capdevilla, J.; Starling, N.; Chen, E.; Di Bartolomeo, M.; Yoshino, T.; Vlahovic, G.; Zografos, E.; O'donnell, S.; more...
    Oncology Research and Treatment (2024)

    Fulltext@MSK | Save
  • Long-term efficacy and safety of larotrectinib in patients with TRK fusion primary central nervous system (CNS) tumors: An updated analysis
    Meeting Abstract

    Perreault, S.; Spano, J. P.; Nilsson, A.; Deyell, R. J.; Doz, F.; Geoerger, B.; Gumus, M.; Lassen, U. N.; Nysom, K.; Valero-Arrese, L.; more...
    Neuro-Oncology (2024)

    Fulltext@MSK | Save
  • Central nervous system bridging radiotherapy (CNS-BRT) achieves rapid cytoreduction prior to car T-cell therapy for aggressive B-cell lymphomas
    Meeting Abstract

    Cederquist, G.; Schefflein, J.; Devlin, S.; Shah, G.; Shouval, R.; Hubbeling, H.; Tringale, K.; Fregonese, B.; Hajj, C.; Boardman, A.; more...
    Neuro-Oncology (2024)

    Fulltext@MSK | Save
  • Patterns of intracranial response and relapse after CNS-directed radiotherapy (CNS-RT) for patients with chemorefractory or progressive secondary CNS lymphoma (SCNSL)
    Meeting Abstract

    Cederquist, G.; Tringale, K.; Hajj, C.; Moore, Z.; Hubbeling, H.; Dreyfuss, A.; Fregonese, B.; Falchi, L.; Scordo, M.; Grommes, C.; more...
    Neuro-Oncology (2024)

    Fulltext@MSK | Save